Difficulty accessing data from randomised trials of drugs for heart failure: a call for action by Fleetcroft, R et al.
Difficulty accessing data from randomised trials of
drugs for heart failure: a call for action
When Robert Fleetcroft and colleagues attempted a systematic review of the treatment of heart
failure, they were unable to answer their research question because of poor reporting and
non-disclosure of data. And yet the necessary studies had been done. Here they discuss their
experience and possible solutions
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Access to individual patient data from published research has
the potential to improve patient outcomes by enabling
researchers to answer new questions with existing data, to
validate findings, and to combine the power from individual
studies, for example in meta-analyses.1 It may also deter
selective reporting and analysis, and research fraud. Difficulty
accessing data from clinical trials means that only part of the
evidence is available, which may lead to erroneous clinical
decisions.
A survey of corresponding authors of clinical trials found that,
although in principle they agreed with sharing their data, they
also had concerns about appropriate data use, investigator or
funder interests, and protection of trial participants.2 Sometimes
data are not available because the trial was not published. For
example, the Carcinoembryonic Antigen Second Look Trial in
colorectal cancer was not published until over 20 years after
completion and reported no benefit for the common use of
carcinoembryonic antigen to detect and resect disseminated
cancer.3 Barriers to accessing data have led to delays in
determining the effectiveness or adverse effects of commonly
used drugs such as oseltamivir, rofecoxib, and rosiglitazone.4-6
To make research data more widely available several journals
and funders have published statements supporting data sharing
for all published articles.1 7-10 The Association of Medical
Research Charities (AMRC) in the United Kingdom, the
European Medicines Agency, and the Institute of Medicine in
the United States all recommend data sharing between
researchers.11-13
Here, we describe our experiences trying to access patient data
for a systematic review of drugs for heart failure—although the
necessary studies had been published, we were unable to answer
our review question owing to poor reporting and non-disclosure
of data. We discuss possible solutions.
Unanswered questions in treating heart
failure
Heart failure is a common condition, affecting 0.7% of the
English population in 2013-14.14Most patients with heart failure
have only minor symptoms; one study has reported that 83%
of patients with heart failure in primary care in the UK have
mild symptoms, classified as class I (no dyspnoea) or class II
(slight to moderate dyspnoea on exercise) on the New York
Heart Association (NYHA) scale.15 However, the National
Institute for Health and Care Excellence (NICE) guidelines for
the management of cardiac failure in primary care rely heavily
on evidence from trials of patients in secondary care, who tend
to have more severe symptoms.16 Thus, drugs for cardiac failure
may be less effective in patients in primary care.17
We conducted a systematic review to determine the effectiveness
of heart failure drugs for patients with NYHA class I and II
symptoms. We included randomised controlled trials of beta
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blockers, angiotensin converting enzyme inhibitors, or
angiotensin receptor blockers. We used standard systematic
review methodology. Two independent reviewers screened the
titles and abstracts for results. A total of 30 studies met the
inclusion criteria.
Searching for evidence
Twenty eight of the 30 studies reported NYHA class in baseline
characteristics, but none included enough data to calculate
outcomes for patients in different NYHA classes.18-47 We
contacted the corresponding authors (or the first authors where
these details were absent) of each study by email on 28 July
2014, asking for additional summary outcome data stratified by
NYHA class (fig 1⇓).
Twelve studies had no email contact details for the
corresponding or first author, but an internet search found
contact details for six of these. In total 24 authors were
contacted. Six emails were returnedwith a “non-delivery report.”
One of these authors (who was the author of two papers) had
died, and three had left their institutions. A further internet
search found alternative contact details for two of these authors,
and data were again requested leaving four non-delivery reports
that we were unable to follow up.We followed up requests with
a second email on 13 September 2014 if there had been no reply
to the first email (fig 2⇓; see appendix on thebmj.com for further
details of the search results).
Inadequate responses to requests for data
We received six replies in total. Three authors said that data
were not available; one said that only one class of heart failure
patient had been included in their study; one author refused to
supply data stating that “such subgroup analyses are not
appropriate and likely to generate spurious findings;” and one
author recommended that we approach a co-author for additional
data, which we are now following.
Of our 30 requests we received only one response with the
potential for further data to inform our research.We anticipated
that the numbers of patients included in the 30 studies (80 450)
would have been more than sufficient to provide an answer to
our research question. The barriers we experienced were poor
reporting of results in the original publications; inadequate or
outdated contact information for the lead author; no response
to requests for data; and one refusal to release data. Lack of
contact details is partly understandable because 11 of the studies
were published in the 1990s.
Difficulties accessing data
Our findings are surprising in the current climate of increasing
access to information. Outcome data were usually presented for
all classes of heart failure combined, leading to incomplete
reporting of results. Many of the trials were published long
ago—11 in the 1990s, 15 in the 2000s, and four published since
2010. One study was retracted in 2013.33 Email addresses for
the corresponding author were missing for 12 studies, and a
further six were invalid. One corresponding author had died,
and three reported that the data were no longer available. We
encountered one refusal owing to concerns about misleading
secondary analysis of their data.
Wewere surprised by the extent of the difficulties we had, given
that a cross sectional survey of corresponding authors on the
sharing of their clinical trial data found that 77% had granted
at least one data sharing request.2 Some authors may refuse to
release data because they think that they have intellectual
property rights.48 or that the data will be misinterpreted and
cause harm.2We acknowledge that intellectual property concerns
may be potentially a big obstacle, but we do not think it valid
to withold data when there is a public interest and where the
results are expected to influence healthcare.
What next?
Ethical approval for future randomised controlled trials of drugs
for heart failure in patients with mild symptomsmay be difficult
to obtain as guidelines have already been published.49-51 And
they may be unnecessary because substantial numbers of these
patients have already been included in these 30 published
studies.
Plans to improve access to data from clinical trials are underway,
and we agree with the suggestions from the AMRC and the
Institute ofMedicine. The AMRC calls for guidelines to govern
the handling of personal health information and for standardised
models for gathering and sharing data. It recommends that the
UK government engages with Europe to ensure that updated
data protection legislation supports secure access to patient data
for research. However it does not make detailed
recommendations on how data sharing might happen.
The Institute of Medicine recommends the sharing of full
analysable datasets for clinical trials within 18 months of study
completion.13 It says that funders and sponsors should develop
a mechanism for data sharing in accordance with the terms and
conditions of grants and contracts; that disease advocacy
organisations should require data sharing plans as part of
protocol reviews and criteria for funding grants; that regulatory
and research bodies should work internationally to support the
responsible sharing of clinical trial data; that research ethics
committees should consider data sharing plans when assessing
the benefits and risks of clinical trials; and that research
institutions and universities should ensure data sharing.
The next stage is for mechanisms of data sharing to be
developed. We need central national repositories for trial data
based in the country of the trial sponsor, accessible to
researchers after 18 months. Possible repositories in the UK
include the UK data archive, which already provides access to
research data from many observational studies, or the Health
Research Authority, as recommended by the AMRC. This will
require coordinated actions from funders, journals, ethics
committees, and national guideline developing bodies.
Guideline developers such as NICE have an important role. We
think it is unacceptable for NICE to make decisions about new
drugs based on clinical effectiveness data that are not in the
public domain. Such transparency is essential to bolster trust in
the process of evaluation of new treatments and technologies.
Research ethics and funding committees should make future
access to the raw data a mandatory requirement of their
approvals. Access to raw data is mentioned in section 52 of the
UK Integrated Research Application System ethics application,
but only in terms of ensuring the anonymity of patient
identifiable data when publishing the results.
Funders could, for example, withhold the final part of grant
funding until individual data are made publicly accessible, in
the same way that some funders withhold final payment until
they have receipt of a satisfactory final report. They should also
provide adequate funding to cover the costs of archiving data
and should insist that arrangements for archiving are discussed
in the protocol. Journals could require evidence of archived data
as a condition of publication of clinical trials, in the same way
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that they currently require evidence of ethical committee
approval.
However, these recommendations will not tackle the problem
of accessing historical data. We encountered difficulties
identifying corresponding authors from older clinical trials,
authors refusing to release data, and datasets that were no longer
available. Others have had difficulties with older data formats,
coding changes in computer software, and use of stored paper
data.52Authors may not agree on who owns the dataset and have
concerns about intellectual property rights and other legal
issues.53 This is contentious—it has been suggested that the data
really belong to the patients, and the researcher is merely the
custodian.54
Lack of informed consent can be a concern if data are not
anonymous or where historical consent was used. The Health
Research Authority standard consent form now includes consent
for anonymous data sharing with other researchers. Considerable
time and cost may be spent trying to access historical data,
especially if they are in paper format. These barriers prevent an
easy solution to accessing historical data, but progress can be
made. Guideline committees could insist on data sharing
agreements for the research they use, which would encourage
authors of historical and important studies to share their data,
but this is a complex issue. Guidelines should include all
relevant data but the research quality of a particular guideline
could be downgraded or given a “health warning” if those data
are not shared, so that this information is transparent to the users
of the guideline.
Although it would not be feasible for all data from historical
trials to be placed in a repository, the Wellcome Trust has
suggested the storage of historical data from priority research
areas such as cardiovascular disease and cancer.55Until data are
openly shared and researchers can undertake secondary analyses,
unnecessary trials will continue to take place and the evidence
base supporting best clinical practice will be harder to identify.
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Key messages
The evidence base for the benefits of drugs for patients with mild heart failure is not clear, so we tried to perform a systematic review
based on published trials
Access to requested data on the outcomes of treatment for patients with mild heart failure was not possible for 29 of the 30 studies we
identified
Difficulties with access to patient data from published studies are well known and several organisations have recommended improvements
Mechanisms for data sharing need to be developed, such as central national repositories for trial data
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